Journal Watch · Journal of Immunology · 2026
Viral-specific induction of cellular and soluble urokinase plasminogen activator receptor (suPAR) expression.
Elevated suPAR liberation was observed after murine CoV infection but not IAV infection-both of which led to increased MO/Mφ mRNA and cell-bound uPA and uPAR, and increased secreted uPA activity. uPA knockdown in MO/Mφs abrogated suPAR liberation and blunted tumor necrosis factor (TNF)-α, interleukin (IL)-1β, and IL-6 induction post-CoV, suggesting that targeting co-regulators of uPAR and uPA may be beneficial in attenuating coronavirus-driven inflammatory cytokine responses, and treating diseases characterized by suPAR release from Mφs.
TL;DR
Elevated suPAR liberation was observed after murine CoV infection but not IAV infection-both of which led to increased MO/Mφ mRNA and cell-bound uPA and uPAR, and increased secreted uPA activity. uPA knockdown in MO/Mφs abrogated suPAR liberation and blunted tumor necrosis factor (TNF)-α, interleukin (IL)-1β, and IL-6 induction post-CoV, suggesting that targeting co-regulators of uPAR and uPA may be beneficial in attenuating coronavirus-driven inflammatory cytokine responses, and treating diseases characterized by suPAR release from Mφs.
Key findings
- Elevated suPAR liberation was observed after murine CoV infection but not IAV infection-both of which led to increased MO/Mφ mRNA and cell-bound uPA and uPAR, and increased secreted uPA activity. uPA knockdown in MO/Mφs abrogated suPAR liberation and blunted tumor necrosis factor (TNF)-α, interleukin (IL)-1β, and IL-6 induction post-CoV, suggesting that targeting co-regulators of uPAR and uPA may be beneficial in attenuating coronavirus-driven inflammatory cytokine responses, and treating diseases characterized by suPAR release from Mφs.
What they did
How suPAR liberation from MO/Mφs occurs after CoV infection, and whether suPAR induction is exclusive to coronavirus infection or occurs from other clinically significant coagulopathy-inducing pneumotropic viral infections such as influenza A (IAV), is unknown. We noted increased PLAUR transcripts in peripheral blood mononuclear cells (PBMCs) from SARS-CoV-2-positive and IAV-positive patients.
Full abstract (original)
Background: Urokinase (uPA) and urokinase plasminogen activator receptor (uPAR/PLAUR) mediate fibrinolysis and matrix remodeling. Liberation of monocyte/macrophage (MO/Mφ)-bound soluble uPAR (suPAR) occurs after infection with coronaviruses (CoVs) such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), correlating with systemic inflammatory stress and end-organ injury severity.
What they did: How suPAR liberation from MO/Mφs occurs after CoV infection, and whether suPAR induction is exclusive to coronavirus infection or occurs from other clinically significant coagulopathy-inducing pneumotropic viral infections such as influenza A (IAV), is unknown. We noted increased PLAUR transcripts in peripheral blood mononuclear cells (PBMCs) from SARS-CoV-2-positive and IAV-positive patients.
Results & conclusions: Elevated suPAR liberation was observed after murine CoV infection but not IAV infection-both of which led to increased MO/Mφ mRNA and cell-bound uPA and uPAR, and increased secreted uPA activity. uPA knockdown in MO/Mφs abrogated suPAR liberation and blunted tumor necrosis factor (TNF)-α, interleukin (IL)-1β, and IL-6 induction post-CoV, suggesting that targeting co-regulators of uPAR and uPA may be beneficial in attenuating coronavirus-driven inflammatory cytokine responses, and treating diseases characterized by suPAR release from Mφs.
Abstract © the authors / Journal of Immunology (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1093/jimmun/vkaf365 · PubMed 41764719.
Why it matters for pharma & biotech
- Directly relevant to teams in mRNA / delivery technology — the abstract reports new data in that space, so competitive and pipeline teams should read the full text.
- Because it reports human data, it can inform indication, endpoint and comparator decisions faster than preclinical work.
- For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.
Modalities & themes detected: mRNA / delivery technology
Limitations & what to check in the full text
- This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
- The work is preclinical. Results in animal or cell models frequently do not translate directly to human efficacy or safety.
- The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.
Frequently asked questions
What did this Journal of Immunology study find?
Elevated suPAR liberation was observed after murine CoV infection but not IAV infection-both of which led to increased MO/Mφ mRNA and cell-bound uPA and uPAR, and increased secreted uPA activity. uPA knockdown in MO/Mφs abrogated suPAR liberation and blunted tumor necrosis factor (TNF)-α, interleukin (IL)-1β, and IL-6 induction post-CoV, suggesting that targeting co-regulators of uPAR and uPA may be beneficial in attenuating coronavirus-driven inflammatory cytokine responses, and treating diseases characterized by suPAR release from Mφs.
What type of study is this?
It is a preclinical (animal / model) study, published in Journal of Immunology in 2026. How suPAR liberation from MO/Mφs occurs after CoV infection, and whether suPAR induction is exclusive to coronavirus infection or occurs from other clinically significant coagulopathy-inducing pneumotropic viral infections such as influenza A (IAV), is unknown.
Where can I read the original paper?
The original is at the publisher via DOI 10.1093/jimmun/vkaf365. PubMed ID: 41764719. BioStudioAI reproduces the abstract for discussion and links to the source.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/viral-specific-induction-of-cellular-and-soluble-urokinase-plasminogen-a-kaf365/
Reading papers is step one. Analysing the data is the work.
BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.
Open BioStudioAI More guides